

C-RAD AND SEETREAT PARTNER TO CO-DEVELOP PERSONALISED RADIOTHERAPY FOR EVERY PATIENT IN EVERY CLINIC

C-RAD AB (publ) the global leader in surface-guided radiation therapy (SGRT), and SeeTreat Pty Ltd, a pioneer in the adaptive decision support radiotherapy (ART) software, today confirm a partnership to co-develop more connected, intelligent, and patient-centric radiotherapy workflows.

In 2027, the partners will bring together two complementary technologies: C-RAD's Catalyst# HD platform, which provides patient setup and real-time motion monitoring, and SeeTreat's ART.1, which delivers automated adaptive plan decision support for every patient at every treatment. The joint platform will support clinical teams to make faster, better-informed decisions to improve patient care.

"Radiation oncology needs connected systems, not isolated tools. That is why we are building an open workflow platform, and we are proud to welcome SeeTreat as our first partner. Together, we combine C-RAD's positioning and motion management expertise with SeeTreat's adaptive decision support, bringing us closer to a truly integrated treatment ecosystem." says Chief Executive Officer, Tomas Blomquist.

"SeeTreat's vision is to reduce the burden of cancer at scale with integrated software technology and we're excited to partner with C-RAD, the global leader for Surface Guided Radiation Therapy and automatic patient workflow, to accelerate realising that vision". says CEO and Founder of SeeTreat, Dr Trang Nguyen.

Both companies share a commitment to bringing advances to radiotherapy departments of all sizes and any treatment machines — from major cancer centres to community clinics where resources may be limited, but the need for precision and efficiency is just as critical.

Clinical teams interested in learning more are invited to meet C-RAD and SeeTreat at ASTRO 2026 in Boston.

For further information:

Tomas Blomquist, CEO, +46 (0)70 523 0163, investors@c-rad.com
Linda Frölén, CFO, +46 (0)70 303 3253, investors@c-rad.com

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

About SeeTreat

SeeTreat is a doctor backed, physics led, software medical device company founded in 2023, led by Dr Trang Nguyen, Ms Antonia Dalton and Professor Paul Keall. The vision is to reduce the burden of cancer through broadly accessible software technology that improve quality and accuracy of treatment. SeeTreat is a global company with a current install base in the UK, Europe, USA and Australia. SeeTreat ART.1 product for offline adaptive assessment is the world-first automated software for adaptive radiotherapy. Headquarters are based in Sydney, Australia.

For more information visit <https://www.seetreatmedical.com/> and follow SeeTreat on LinkedIn at: <https://www.linkedin.com/company/seetreat-medical>

Attachments

C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic